Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
A Japanese health ministry panel on July 22 discussed the potential routine use of the MMR vaccine Mimrit, agreed to add information on RSV antibody Enflonsia (clesrovimab) to the existing RSV prevention fact sheet, and continued deliberations on male HPV…
To read the full story
Related Article
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout
June 22, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
- MHLW Panel Clarifies Roles in Vaccine Policy Review Process
May 21, 2026
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
REGULATORY
- Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
- Cabinet Office Seeks 22 Billion Yen for Clinical Trial Subsidies
September 1, 2026
- US MFN Could Steer Clinical Trials Away from Japan: MHLW Bureau Chief
September 1, 2026
- Suspected Drug Promotion Violations Hit Record Low in FY2025: MHLW
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…